Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease

Heart

Volumn 98, Issue 5, 2012, Pages 408-413

  Read, Philip A ^a   Khan, Fakhar Z ^a   Dutka, David P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CROSSOVER PROCEDURE; DRUG SAFETY; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE WALL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPOGLYCEMIA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; STRESS ECHOCARDIOGRAPHY; TISSUE DOPPLER IMAGING; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

CARDIOTONIC AGENTS; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; CROSS-OVER STUDIES; DOBUTAMINE; ECHOCARDIOGRAPHY, STRESS; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84857111888     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.219345     Document Type: Article

References (34)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-39.
2. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30.
3. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705.
4. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995;358:219-24.
5. Zhao T, Parikh P, Bhashyam S, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006;317:1106-13.
6. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004;25:634-41.
7. Vanoverschelde JL, Janier MF, Bakke JE, et al. Rate of glycolysis during ischemia determines extent of ischemic injury and functional recovery after reperfusion. Am J Physiol 1994;267:H1785-94.
8. Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004;110:955-61.
9. Nikolaidis LA, Doverspike A, Hentosz T, et al. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 2005;312:303-8.
10. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-5.
11. Read PA, Khan FZ, Heck PM, et al. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010;3:195-201.
12. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond) 2005;108:277-92.
13. Pellerin D, Sharma R, Elliott P, et al. Tissue Doppler, strain, and strain rate echocardiography for the assessment of left and right systolic ventricular function. Heart 2003;89(Suppl 3):iii9-17.
14. Marwick TH. Measurement of strain and strain rate by echocardiography: ready for prime time? J Am Coll Cardiol 2006;47:1313-27.
15. Madler CF, Payne N, Wilkenshoff U, et al. Non-invasive diagnosis of coronary artery disease by quantitative stress echocardiography: optimal diagnostic models using off-line tissue Doppler in the MYDISE study. Eur Heart J 2003;24:1584-94.
16. Voigt JU, Exner B, Schmiedehausen K, et al. Strain-rate imaging during dobutamine stress echocardiography provides objective evidence of inducible ischemia. Circulation 2003;107:2120-6.
17. Voigt JU, Nixdorff U, Bogdan R, et al. Comparison of deformation imaging and velocity imaging for detecting regional inducible ischaemia during dobutamine stress echocardiography. Eur Heart J 2004;25:1517-25.
18. Green CJ, Frazer RS, Underhill S, et al. Metabolic effects of dobutamine in normal man. Clin Sci (Lond) 1992;82:77-83.
19. Bolli R. Mechanism of myocardial "stunning". Circulation 1990;82:723-38.
20. Barnes E, Hall RJ, Dutka DP, et al. Absolute blood flow and oxygen consumption in stunned myocardium in patients with coronary artery disease. J Am Coll Cardiol 2002;39:420-7.
21. Taegtmeyer H, Roberts AF, Raine AE. Energy metabolism in reperfused heart muscle: metabolic correlates to return of function. J Am Coll Cardiol 1985;6:864-70.
22. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation 1999;99:578-88.
23. Sokos GG, Bolukoglu H, German J, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007;100:824-9.
24. Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54:146-51.
25. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008;117:2340-50.
26. Nikolaidis LA, Elahi D, Shen YT, et al. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005;289:H2401-8.
27. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008;146:243-9.
28. Bhashyam S, Fields AV, Patterson B, et al. Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail 2010;3:512-21.
29. Mehta SR, Yusuf S, Diaz R, et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005;293:437-46.
30. Zhao YT, Weng CL, Chen ML, et al. Comparison of glucose-insulin-potassium and insulin-glucose as adjunctive therapy in acute myocardial infarction: a contemporary meta-analysis of randomised controlled trials. Heart 2010;96:1622-6.
31. Deedwania P, Kosiborod M, Barrett E, et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008;117:1610-19.
32. Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-9.
33. Lankisch M, Futh R, Schotes D, et al. High prevalence of undiagnosed impaired glucose regulation and diabetes mellitus in patients scheduled for an elective coronary angiography. Clin Res Cardiol 2006;95:80-7.
34. Heck PM, Hoole SP, Khan SN, et al. Hyperinsulinemia improves ischemic LV function in insulin resistant subjects. Cardiovasc Diabetol 2010;9:27.